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Daylight-mediated photodynamic therapy (DL-PDT) is 
considered as effective as conventional PDT using artifi-
cial light (light-emitting diode (LED)-PDT) for treatment 
of actinic keratoses (AK). This randomized prospective 
non-sponsored study assessed the cost-effectiveness of 
DL-PDT compared with LED-PDT. Seventy patients 
with 210 AKs were randomized to DL-PDT or LED-PDT 
groups. Effectiveness was assessed at 6 months. The costs 
included societal costs and private costs, including the 
time patients spent in treatment. Results are presented 
as incremental cost-effectiveness ratio (ICER). The total 
costs per patient were significantly lower for DL-PDT 
(€132) compared with LED-PDT (€170), giving a cost 
saving of €38 (p = 0.022). The estimated probabilities for 
patients’ complete response were 0.429 for DL-PDT and 
0.686 for LED-PDT; a difference in probability of being 
healed of 0.257. ICER showed a monetary gain of €147 
per unit of effectiveness lost. DL-PDT is less costly and 
less effective than LED-PDT. In terms of cost-effective-
ness analysis, DL-PDT provides lower value for money 
compared with LED-PDT. Key words: actinic keratoses; 
cost-effectiveness; daylight-photodynamic therapy.
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Actinic keratoses (AK) are precursors with potential to 
develop into metastatic squamous cell carcinoma (SCC) 
(1). High incidence rates of AKs raise a significant 
economic issue. The prevalence of AK is estimated to 
be approximately 50% in Australia and 11–34% in the 
Northern hemisphere, with higher prevalence among 
elderly subjects (2–4). The total annual direct costs for 
AKs were 18 million Euros (€) in Sweden in 2011 and 
1.2 billion USD in the US in 2004 (5, 6).
There are several topical treatment options for AKs 
(7, 8). Photodynamic therapy (PDT) is a recommended 
treatment option (9–11). A novel approach, using day-
light (DL-PDT) in the treatment of AKs is considered 
to be as effective as treatment with conventional PDT 
using artificial light (light-emitting diode (LED)-PDT) 
(12, 13). The use of DL-PDT is thought to be less costly 
due to shorter visiting times at the clinics (13, 14). To 
our knowledge, the cost-effectiveness of DL-PDT for 
the treatment of AK has not been studied previously. 
This study was a prospective randomized non-spon-
sored trial to assess the cost-effectiveness of DL-PDT 
compared with LED-PDT in the treatment of AKs. 
MATERIALS AND METHODS
The study protocol followed the Declaration of Helsinki and 
was approved by the local ethics committee. All participants 
provided informed consent. For full details, see Appendix S11.
All patients who fulfilled the inclusion criteria were sequen-
tially recruited from the Department of Dermatology, Päijät-
Häme Central Hospital between 2011 and 2013. Inclusion 
criteria included a minimum of 3 clinically clearly detectable 
AKs on facial or scalp areas. Exclusion criteria are detailed in 
Appendix S11.
Patients were randomized to receive either DL-PDT or LED-
PDT. Before treatments AK lesions were photographed, counted 
and classified into grades I–III (16).Three clearly detectable 
target lesions per patient were chosen for the study follow-up. 
If patients had more than 3 lesions, all lesions were treated 
according to the randomization. Grade I lesions were treated 
once and grades II–III lesions twice. The treatment procedure 
is detailed in Appendix S11. 
Response was evaluated clinically (patient complete re-
sponse, 3 target lesions cleared) at 6 months. Effectiveness was 
defined by the level as the probability of patient’s complete 
response at 6 months. 
Costs included societal costs (including the working time 
of the nurse and doctor, treatment room rent, medication and 
equipment) and patients’ costs (including treatment time and 
travel costs). The analysis adopted a societal perspective, 
including both healthcare and patients’ costs (Table I). The 
costs of control visits or further treatments were not included. 
Cost-effectiveness analysis (CEA) was performed using DL-
PDT and LED-PDT as the intervention and control treatments, 
respectively, generating the incremental cost-effectiveness 
ratio (ICER). For a detailed description of the method, see 
Appendix S11.
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RESULTS
Patients
Of the 73 randomized patients 3 were excluded; one due 
to an unrelated death, one for diagnosed SCC on the 
studied area before treatment, and one for severe diffuse 
photo-damage that hindered the count of AKs (Fig S11).
A total of 70 patients completed the study, 39 men and 
31 women, age range 59–93 years (mean 76 years). Eight 
patients had anamnestic skin photo-type I, 25 photo-type 
II, 34 photo-type III, and 3 photo-type IV. Forty-six pa-
tients had earlier received treatment for their AKs and 3 
for carcinoma in situ. Six had had operations for SCC, 
18 for basal cell carcinoma (BCC), 1 for melanoma and 
one for verrucous carcinoma, of which 2 BCCs, one SCC 
and verrucous carcinoma were in the studied skin areas. 
Twenty-four patients had previously received cryosur-
gery, 8 DL-PDT and 11 LED-PDT for AKs on the studied 
areas. In addition, 5 patients had received LED-PDT, 23 
cryosurgery, 1 imiquimod, 1 diclofenac and 1 topical 
retinoid treatment for AKs in other skin areas. None of 
the patients had received both DL-PDT and LED-PDT. 
There was a wash-out period of at least 6 months from 
previous treatments to the studied areas. 
Thirty-five patients received DL-PDT and 35 recei-
ved LED-PDT. Seven patients in both groups received 
2 treatments for thicker lesions 7–23 days apart (mean 
12 days) and the rest received one treatment session. 
The mean time for daylight-exposure was 161 min 
(range 120–480 min). Patients did not visit or contact 
the hospital between treatments and control visits.
Three target lesions per patient were included in the 
study; thus, the number of lesions studied was 210, of 
whom 105 (92 grade I, 13 grade II–III) were treated with 
DL-PDT and 105 (93 grade I and 12 grade II–III) with 
LED-PDT (p = 0.46). Patient complete response rates (3/3 
lesions cleared) were 15 of 35 (42.9%) with DL-PDT and 
24 of 35 (68.6%) with LED-PDT (p = 0.030) (Fig S11). 
To better compare our results with previous DL-PDT 
studies, we also conducted per lesion clearance analysis. 
At 6 months LED-PDT cleared 94 of 105 (89.2%) and 
DL-PDT 76 of 105 (72.4%) lesions (p = 0.0025). In 
the LED-PDT group 93 grade I AKs receiving 1 and 
12 grade II–III AKs 2 treatments showed 88.2% and 
100% complete clearance, respectively (p = 0.36). In 
the DL-PDT group 92 grade I AKs received 1 treatment 
and 13 grade II–III AKs 2 treatments with 73.9% and 
61.5% clearance rates (p = 0.34).
Costs
The imputed mean total costs per patient (1–2 treat-
ments) were €132 (95% confidence interval (CI) 111.3–
152.6) for DL-PDT and €170 (95% CI 126.0–213.5) 
for LED-PDT, resulting in incremental costs savings 
of –€38 (p = 0.022) (Table I). 
Cost-effectiveness
The probabilities for patients’ complete response were 
0.429 (95% CI 0.414–0.443) for DL-PDT and 0.686 
(95% CI 0.674–0.698) for LED-PDT, thus yielding a loss 
in the probability of being healed of 0.257. The ICER 
revealed a monetary gain of €147 per unit of effectiveness 
lost (Table II). The cost-effectiveness (CE)-plane showed 
that approximately 96% of the bootstrapped replica data 
yielded a result that lies in the south-western part of the 
plane, indicating that DL-PDT provided a lower value 
for money compared with LED-PDT (Fig S21).
Additional data analysis
When dividing the mean cost per patient with the 
estimated probability for patient’s 
complete response, the costs per 
complete responders were calcula-
ted as €308 for DL-PDT and €248 
for LED-PDT (p = 0.004).
DL-PDT required significantly 
less of the nurses’ time (median 51 
vs. 78 min per treatment, p = 0.003) 
and less of the patients’ treatment 
time (median 194.5 vs. 271 min, 
p < 0.0001) compared with LED-
PDT. 
As measured with the visual analo-
gue scale (VAS, range 0–10) during 
and after the treatments until the pain 
had vanished, DL-PDT was signi-
ficantly less painful, with a mean 
maximal pain value of 1.53 (range 
0.1–6.0) compared with LED-PDT 
4.36 (range 0.3–8.4), p < 0.001).
Table I. Cost items, unit cost and mean total costs of daylight-mediated photodynamic 
therapy (DL-PDT) compared with light-emitting diode PDT (LED-PDT) for treatment 
of actinic keratoses (AK) (p = 0.022)
Cost item Unit costs
DL-PDT, € 
n = 35a 
Mean ± SD
LED-PDT, € 
n = 35a 
Mean ± SD
Societal costs
  Nurses’ time with the patient €19/h 17.1 ± 4.3 24.9 ± 6.6
  Doctors’ time (resident) for the treatment €30.2/h 9.0 ± 3.0 9.0 ± 3.0
  Treatment room rent €1.5/h 1.4 ± 0.3 2.0 ± 0.5
  Photosensitizer (methylaminolaevulinate) €163/g 37.2 ± 26.3 50.4 ± 31.8
  Anaesthetic €0.3/ml 0.25 ± 0.56 0.23 ± 0.53
  Sunscreen €0.1/ml 1.6 ± 0.53 –
  Occlusion membrane €0.3/20 cm – 0.35 ± 0.12
  LED light €0.14/illumination – 0.16 ± 0.05
  Hospitalization €385/nightb – 11 
Patients’ costs
  Patients’ (pensioner) time used for the treatment €8.6/h 40.4 ± 23.0 49.6 ± 21.8
  Patients’ travel costs €0.45/km 25.0 ± 22.1 22.1 ± 30.9
Mean total costs 132 ± 62.3 170 ± 132.0
a28/35 patients received one treatment session, 7/35 patients received 2 treatments for grade II–III 
AKs. bOnly 1 patient spent a night at the hospital due to pain in the treatment area after LED-PDT.
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DISCUSSION
The results of this study show that DL-PDT is less 
costly, but also less effective, than LED-PDT. DL-
PDT was associated with an incremental cost saving 
of €147 and a decremental probability of being healed 
of –0.257. Thus, DL-PDT provides a lower value for 
money compared with LED-PDT.
The cost-effectiveness of LED-PDT compared with 
other treatments for AK has been evaluated in several stu-
dies. A limitation of many of these studies compared with 
our prospective study using accurate costs is that they use 
estimated costs; some of the studies included only the cost 
of the topical drug. To our knowledge there have been no 
cost-effectiveness evaluations of DL-PDT. The simulated 
costs per complete responder were €379 for MAL-PDT 
and €363 for cryotherapy, including the cost of yearly 
re-treatments, and valuing the cosmetic outcome. The 
incremental cost per extra complete responder was €401, 
with MAL-PDT being more expensive (18). When LED-
PDT was compared with imiquimod using a decision-tree 
model estimating quality-adjusted life years (QALYs) and 
treatment costs, it was implied that imiquimod might be 
more cost-effective (19). A recent prospective head-to-
head study found that MAL-PDT was more cost-effective 
compared with diclofenac + hyaluronic acid gel (DHA), 
with the costs per complete responder being €566.7 and 
€1,026.2 for MAL-PDT and €595.2 and €2,295.2 for DHA 
at 3 and 12 months, respectively (20). Our study showed 
that the costs per complete responder were €308 for DL-
PDT and €248 for LED-PDT at 6 months. A limitation of 
our study is that we did not include the costs of further tre-
atments or the quality of life analysis (QALY), and thus the 
numbers are not directly comparable with previous data. 
PDT studies rarely report response rates at the patient 
level. In the Italian study, the patient complete response 
rate for LED-PDT was 68.4% at 3 months and 55.2% at 
1 year (19). In another study, MAL-PDT was superior to 
a placebo, with a patient complete response of 59.2% vs. 
14.9% at 3 months (21). Our results are in concordance 
with these findings, showing a 68.6% patient complete 
response rate for LED-PDT at 6 months. Our patient 
complete response rate for DL-PDT was 42.9%. To 
our knowledge, the patient complete response for DL-
PDT has not been reported earlier. As patient complete 
response is a major indicator of the need of further 
treatments and further costs, future research should 
focus more attention on this subject. 
The majority of PDT studies report lesion clearance 
rates ranging from 71% to 92% for LED-PDT, and from 
75.9% to 79.5% for DL-PDT (10, 13, 14, 22, 23). Our 
results show equal clearance rates for LED-PDT (89.2%), 
but slightly lower clearance rates for DL-PDT (72.4%). 
The slightly lower efficacy rates for DL-PDT could be 
explained by a longer follow-up period (6 months) than 
in the previous studies reporting 3-month clearance rates. 
A few facts might have affected our DL-PDT effec-
tiveness results2. 
Despite its higher efficacy, LED-PDT might not be 
an attractive option for patients, as the use of DL-PDT 
results in significantly less pain and time spent at the 
clinic. Thus, we still prefer the use of DL-PDT over 
the conventional treatment during the summer months. 
With its short visit time, DL-PDT can be implemented 
in private practices, which could reduce the burden 
on public clinics. A further CEA analysis of DL-PDT 
should be conducted including QALYs and patient pre-
ference. Furthermore, the cost-effectiveness of newer 
Table II. Incremental cost-effectiveness ratio (ICER)
Effectiveness (E) Costs (C) ICER
Probability 
of complete 
response 
Incremental 
effectiveness
Per 
patient 
€
Incre-
mental 
cost
€/Probability 
of complete 
response
DL-PDT 0.429 132
LED-PDT 0.686 –0.257 170 –38 147
DL-PDT: daylight-mediated photodynamic therapy; LED-PDT: light-emitting 
diode photodynamic therapy.
2Meteorological studies have shown that DL-PDT can be implemented in 
Reykjavik (located in the same latitude (64°N) with Finland) until the middle 
of September (24). In the first 2 years we continued treatments until early 
October, which influenced the response rates. Of the 14 patients treated in late 
September to early October only 16.7% (1/6) in the DL-PDT group and 87.5% 
(7/8) in the LED-PDT group were completely cleared. Thus, the treatment 
should be limited to the summer months in northern countries. However, 
the most effective light-dose needed for DL-PDT remains unclear. We did 
not use light-dosimeters for DL-PDT and thus accurate light doses are not 
available. We used a different sunscreen (ACO Sun Kids High Protection 
Sun Spray® SPF 30, ACO) from that used in previous studies (14). However, 
the absorption spectrum only minimally overlapped the blue light region and 
thus was assumed not to affect treatment outcome. A 0.25-mm thick layer of 
MAL cream has been approved as sufficient for DL-PDT, resulting in 74% 
lesion complete clearance (25). To our knowledge the efficacy of <1-mm 
layer photosensitizer has not been studied for LED-PDT. Thus, in our study, 
the DL-PDT group received a thinner layer of MAL cream (0.25 mm) than 
the LED-PDT group (1 mm), which reduced the costs for DL-PDT, but also 
may have affected the response rate. In LED-PDT we used the standardized 
protocol of a 1-mm thick layer of the photosensitizer under 3 h occlusion, 
while no occlusion was used in DL-PDT. This results in higher amounts of 
protoporphyrin IX (PpIX) in the tissues of the LED-group than in the DL-
group; in the latter PpIX is activated while developing (13). A larger trial 
evaluating different thicknesses of MAL cream in LED-PDT is warranted.
The present study found DL-PDT to be significantly less painful compared 
with LED-PDT. A limitation is that this finding and patient preference were 
not included in assessment of QALYs and the CEA analysis. LED-PDT might 
not be an attractive option for patients, as the use of DL-PDT significantly 
lowers pain and time spent at the clinic. An earlier split-face study comparing 
LED-PDT and DL-PDT reported higher patient preference for DL-PDT 
(13). Further limitations to our study include the lack of investigator-blinded 
outcome evaluation and assessment of adverse reactions. We did not perform 
skin biopsies to verify AK diagnoses, and despite the high accuracy of clinical 
diagnoses this should be considered a limitation (26). To simplify the treatment 
process for cost evaluation we used a treatment method targeted to lesions. 
Had we targeted the whole field, the cost of the treatment would have been 
higher and this may have affected the CEA analysis. The results may not be 
easily generalized to the working age population as it focused on pensioners.
Acta Derm Venereol 96
244 N. Neittaanmäki-Perttu et al.
low-concentration photosensitizers in DL-PDT needs 
to be studied (25, 27). 
In conclusion, this study assessing the detailed costs 
of DL-PDT and LED-PDT for treatment of AKs found 
that, in terms of CEA, DL-PDT provides a lower value 
for money compared with LED-PDT.
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